Emerging immunotherapies in melanoma beyond immune checkpoint inhibitors: Vaccines, intralesional therapies, adoptive cell therapies, and T-cell engagers.
BACKGROUND Immune checkpoint inhibitors have transformed the management of melanoma, yet many patients do not achieve durable benefit. Novel immunotherapeutic strategies are being developed in both cutaneous and uveal melanoma. METHODS This narrative review summarizes four classes of emerging immunotherapies: persona...